Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

January 17, 2017

Merck Seeks FDA Approval of Keytruda, Chemotherapy Combo for Certain Lung Cancer Patients

News

The U.S. FDA has accepted for review a supplemental Biologics Licence Application (sBLA) seeking the approval of Keytruda (pembrolizumab) in combination with Alimta (pemetrexed) and Paraplatin (carboplatin) for patients with ... Read more

January 3, 2017

Keytruda Closer to European Approval as Treatment for Some Lung-Cancer Patients

News

European regulators have taken a key step toward authorizing Keytruda (pembrolizumab) as a therapy for certain kinds of metastatic non-small cell lung cancer patients. The European Medicines Agency’s Committee for Medical ... Read more

December 22, 2016December 22, 2016

Melanoma Treatment Holds Promise for Lung Cancer Patients with ATM Mutations, Study Suggests

News

An approved treatment for BRAF-mutant melanomas may be promising for certain lung cancer patients, according to recent data published in Nature Communications. The study, “MEK inhibitors block growth of lung tumours with mutations ... Read more

December 13, 2016

Immunotherapy Combination Shows Promise in Chemotherapy-naive Advanced Lung Cancer Patients

News

Patients with advanced non-small cell lung cancer (NSCLC) who have never received chemotherapy, may benefit from combination of the immunotherapy agents Opdivo (nivolumab) and Yervoy (ipilimumab), according to updated data ... Read more

November 15, 2016November 20, 2016

Identification of Lung Cancer Subtypes May Lead to Better, Tailored Therapies

News

An analysis of more than 1,000 non-small cell lung cancers (NSCLC) has shown that this type of cancer can be divided into nine different subtypes according to its gene expression ... Read more

November 10, 2016November 10, 2016

Therapy Candidate Brigatinib Looks Promising to Treat Certain Lung Cancers

News

The investigational ALK inhibitor brigatinib could be a promising treatment for non-small cell lung cancer (NSCLC) patients who have ALK rearrangements. It showed a favorable clinical activity and an acceptable safety ... Read more

November 1, 2016

Ariad’s New Drug Application of Brigatinib for NSCLC to Be Reviewed by FDA

News

The U.S. Food and Drug Administration (FDA) will review Ariad‘s new drug application (NDA) for brigatinib, an investigational therapy for patients with non-small cell lung cancer (NSCLC) who have progressed following ... Read more

October 27, 2016

Immunotherapy Showing Promise in Treating Advanced Lung Cancer in Phase 1/2 Trial

News

Durvalumab, an experimental immunotherapy drug, may be a potential treatment approach for patients with advanced lung or head and neck cancers, according to preliminary data from a Phase 1/2 trial. Preliminary ... Read more

October 25, 2016October 25, 2016

Keytruda, Chemotherapy Combo Shown as Promising First Line Therapy for Advanced NSCLC

News

Adding Keytruda (pembrolizumab) to standard first-line therapy with Paraplatin (carboplatin) and Alimta (pemetrexed) is a promising approach for patients with inoperable or metastatic nonsquamous non-small cell lung cancer (NSCLC), according to ... Read more

October 21, 2016

Genentech’s Tecentriq for Metastatic Non-small Cell Lung Cancer Gets FDA Approval

News

The FDA has approved Genentech’s Tecentriq (atezolizumab) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed after platinum-based chemotherapy or whose disease continued after another FDA-approved targeted therapy when their tumors had certain ... Read more